Clinical Trial Update: Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating neoadjuvant Firmonertinib combined with chemotherapy for resectable stage II-IIIb EGFR-mutant non-small cell lung cancer; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING